Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Who Took Part

The study group was 2 women.

PubMed tags the participants as both men and women.

HSV-2 serologic testing was done at enrollment and final study visits.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Copper (Supplement) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Within a randomized trial of the effect of 3 contraceptive methods-DMPA-IM, a copper intrauterine device (IUD), and a levonorgestrel (LNG) implant-on human immunodeficiency virus (HIV) acquisition, the researchers assessed HSV-2 acquisition.

Intention-to-treat analysis using Poisson regression with robust standard errors compared HSV-2 incidence by contraceptive method.

What Was Measured

Topics PubMed links to this paper include Contraception, Contraceptive Agents, Female, HIV Infections, Herpes Simplex, Herpesvirus 2, Human, Incidence and Intrauterine Devices, Copper.

The authors tagged it with the keywords Africa, herpes simplex virus type 2 (HSV-2) and women.

What This Means in Plain Language

The paper is a randomized study of Copper (Supplement) in 2 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.